Insights into direct anticoagulants

Elias Saad; Najib Dally

doi:10.1097/mbc.0000000000000291

Insights into direct anticoagulants

Elias Saad, Najib Dally

Bar-Ilan University - Azrieli Faculty of Medicine

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

For the past five decades, vitamin K antagonists (VKA) have been the only class of oral anticoagulants available for treating or preventing venous and arterial thromboembolism. Recently, new oral anticoagulants were developed to address significant restrictions regarding the use of VKAs. These drugs act by direct blockade of activated coagulation factor X (FXa) or thrombin. This present mini-review highlights the pharmacological properties of these new anticoagulants, and discusses the supporting evidence for their usage as well as points to potential advantages and disadvantages of using these novel drugs in clinical practice.

Original language	English
Pages (from-to)	492-498
Number of pages	7
Journal	Blood Coagulation and Fibrinolysis
Volume	26
Issue number	5
DOIs	https://doi.org/10.1097/mbc.0000000000000291
State	Published - 10 Jul 2015

Bibliographical note

Publisher Copyright:
© 2015 Wolters Kluwer Health, Inc.

Keywords

anticoagulants
direct thrombin inhibitors
factor Xa inhibitors
thromboembolism

Access to Document

10.1097/mbc.0000000000000291

Cite this

@article{bf5beaca793649ecb64fb0761aae9786,

title = "Insights into direct anticoagulants",

abstract = "For the past five decades, vitamin K antagonists (VKA) have been the only class of oral anticoagulants available for treating or preventing venous and arterial thromboembolism. Recently, new oral anticoagulants were developed to address significant restrictions regarding the use of VKAs. These drugs act by direct blockade of activated coagulation factor X (FXa) or thrombin. This present mini-review highlights the pharmacological properties of these new anticoagulants, and discusses the supporting evidence for their usage as well as points to potential advantages and disadvantages of using these novel drugs in clinical practice.",

keywords = "anticoagulants, direct thrombin inhibitors, factor Xa inhibitors, thromboembolism",

author = "Elias Saad and Najib Dally",

note = "Publisher Copyright: {\textcopyright} 2015 Wolters Kluwer Health, Inc.",

year = "2015",

month = jul,

day = "10",

doi = "10.1097/mbc.0000000000000291",

language = "אנגלית",

volume = "26",

pages = "492--498",

journal = "Blood Coagulation and Fibrinolysis",

issn = "0957-5235",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Insights into direct anticoagulants

AU - Saad, Elias

AU - Dally, Najib

PY - 2015/7/10

Y1 - 2015/7/10

N2 - For the past five decades, vitamin K antagonists (VKA) have been the only class of oral anticoagulants available for treating or preventing venous and arterial thromboembolism. Recently, new oral anticoagulants were developed to address significant restrictions regarding the use of VKAs. These drugs act by direct blockade of activated coagulation factor X (FXa) or thrombin. This present mini-review highlights the pharmacological properties of these new anticoagulants, and discusses the supporting evidence for their usage as well as points to potential advantages and disadvantages of using these novel drugs in clinical practice.

AB - For the past five decades, vitamin K antagonists (VKA) have been the only class of oral anticoagulants available for treating or preventing venous and arterial thromboembolism. Recently, new oral anticoagulants were developed to address significant restrictions regarding the use of VKAs. These drugs act by direct blockade of activated coagulation factor X (FXa) or thrombin. This present mini-review highlights the pharmacological properties of these new anticoagulants, and discusses the supporting evidence for their usage as well as points to potential advantages and disadvantages of using these novel drugs in clinical practice.

KW - anticoagulants

KW - direct thrombin inhibitors

KW - factor Xa inhibitors

KW - thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84941571082&partnerID=8YFLogxK

U2 - 10.1097/mbc.0000000000000291

DO - 10.1097/mbc.0000000000000291

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 25828968

AN - SCOPUS:84941571082

SN - 0957-5235

VL - 26

SP - 492

EP - 498

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

IS - 5

ER -

Insights into direct anticoagulants

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this